[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100456454":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":34,"locations":44,"responsibleParty":184,"collaborators":11,"id":188,"slug":189,"hasResults":190,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":11,"eligibilityCriteria":194,"healthyVolunteers":190,"sex":195,"minAge":196,"maxAge":11,"enrollmentInfo":197,"targetDuration":11,"studyType":200,"phases":201,"briefSummary":203,"conditions":204,"keywords":11,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":216},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Best systemic therapy (BST) + primary prostate radiation (XRT)","ACTIVE_COMPARATOR",null,[13,14],"Radiation: Prostate radiation (XRT)","Drug: Systemic Therapy",{"label":16,"type":10,"description":11,"interventionNames":17},"BST + XRT + SABR metastasis-directed therapy (MDT)",[13,14,18],"Radiation: Stereotactic ablative radiation therapy (SABR)",[20,25,30],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"RADIATION","Prostate radiation (XRT)","Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.",[16,9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DRUG","Systemic Therapy","All systemic therapy is provided as best prescribed for patient per their medical oncologist.",[16,9],{"type":21,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"Stereotactic ablative radiation therapy (SABR)","SABR is delivered to those randomized to Arm 2.",[16],[35,40],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"Zaker Rana, MD","CONTACT","410-369-5200","zaker.rana@umm.edu",{"name":41,"role":37,"phone":42,"phoneExt":11,"email":43},"Nicole Helie","410-328-6304","nicole.helie@umm.edu",[45,64,79,91,98,112,126,140,155,169],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"UC San Diego Moores Cancer Center","RECRUITING","La Jolla","California","92093","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-117.2742,32.84727,{"lat":57,"lon":56},[60],{"name":61,"role":37,"phone":62,"phoneExt":11,"email":63},"Tyler Seibert, MD, PhD","858-822-6040","tseibert@health.ucsd.edu",{"facility":65,"status":47,"city":66,"state":67,"zip":68,"country":51,"countryCode":52,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"KU Medical Center- Cancer Center","Kansas City","Kansas","66160",{"type":54,"coordinates":70},[71,72],-94.62746,39.11417,{"lat":72,"lon":71},[75],{"name":76,"role":37,"phone":77,"phoneExt":11,"email":78},"Xinglei Shen, MD","913-588-1227","xshen@kumc.edu",{"facility":80,"status":47,"city":81,"state":82,"zip":83,"country":51,"countryCode":52,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Maryland Proton Treatment Center","Baltimore","Maryland","21201",{"type":54,"coordinates":85},[86,87],-76.61219,39.29038,{"lat":87,"lon":86},[90],{"name":41,"role":37,"phone":42,"phoneExt":11,"email":43},{"facility":92,"status":47,"city":81,"state":82,"zip":83,"country":51,"countryCode":52,"cosmosGeoPoint":93,"geoPoint":95,"contacts":96},"UMMC",{"type":54,"coordinates":94},[86,87],{"lat":87,"lon":86},[97],{"name":41,"role":37,"phone":42,"phoneExt":11,"email":43},{"facility":99,"status":47,"city":100,"state":82,"zip":101,"country":51,"countryCode":52,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Upper Chesapeake Health","Bel Air","21014",{"type":54,"coordinates":103},[104,105],-76.34829,39.53594,{"lat":105,"lon":104},[108],{"name":109,"role":37,"phone":110,"phoneExt":11,"email":111},"Lalicia Roman","443-643-1877","lalicia.roman@umm.edu",{"facility":113,"status":47,"city":114,"state":82,"zip":115,"country":51,"countryCode":52,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Central Maryland Radiation Oncology","Columbia","21044",{"type":54,"coordinates":117},[118,119],-76.83942,39.24038,{"lat":119,"lon":118},[122],{"name":123,"role":37,"phone":124,"phoneExt":11,"email":125},"Caitlin Eggleston","410-328-7586","caitlineggleston@umm.edu",{"facility":127,"status":47,"city":128,"state":82,"zip":129,"country":51,"countryCode":52,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Baltimore Washington Medical Center","Glen Burnie","21061",{"type":54,"coordinates":131},[132,133],-76.62469,39.16261,{"lat":133,"lon":132},[136],{"name":137,"role":37,"phone":138,"phoneExt":11,"email":139},"Pilar Strycula, RN, BSN","410-553-8110","Pstrycula@umm.edu",{"facility":141,"status":47,"city":142,"state":143,"zip":144,"country":51,"countryCode":52,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"Sidney Kimmel Cancer Center at Jefferson Health","Philadelphia","Pennsylvania","19107",{"type":54,"coordinates":146},[147,148],-75.16362,39.95238,{"lat":148,"lon":147},[151],{"name":152,"role":37,"phone":153,"phoneExt":11,"email":154},"Jessie DiNome, MD","215-955-8874","Jessie.DiNome@jefferson.edu",{"facility":156,"status":47,"city":157,"state":143,"zip":158,"country":51,"countryCode":52,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"UPMC Hillman Cancer Center","Pittsburgh","15232",{"type":54,"coordinates":160},[161,162],-79.99589,40.44062,{"lat":162,"lon":161},[165],{"name":166,"role":37,"phone":167,"phoneExt":11,"email":168},"Adam Olson, MD","412-623-6720","olsonac2@upmc.edu",{"facility":170,"status":47,"city":171,"state":172,"zip":173,"country":51,"countryCode":52,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Bon Secours Cancer Institute at St. Francis","Midlothian","Virginia","23114",{"type":54,"coordinates":175},[176,177],-77.64916,37.50598,{"lat":177,"lon":176},[180],{"name":181,"role":37,"phone":182,"phoneExt":11,"email":183},"Joseph Pennington, MD","804-266-7762","joseph_pennington@bshsi.org",{"type":185,"investigatorFullName":186,"investigatorTitle":187,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Department of Radiation Oncology","Principal Investigator","100456454","phase-2-terps-trial-for-de-novo-oligometastic-prostate-cancer-100456454",false,"NCT05223803","TERPS Trial for de Novo Oligometastic Prostate Cancer","Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in de Novo oligometaStatic Prostate Cancer (TERPS) Trial","Inclusion Criteria:\n\n1. Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue (with at least one bone metastasis) develop within the past 6-months that are seen on imaging. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or PSMA PET-CT scan.\n\n   1. CT or MRI scan within 6 months of enrollment\n   2. Bone scan within 6 months of enrollment\n   3. Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT\u002FMRI scan and bone scan)\n2. Histologic confirmation of malignancy (primary or metastatic tumor).\n3. Patient may have had prior systemic therapy and\u002For ADT associated with treatment within 9-months of enrollment.\n4. PSA \\> 0.5 but \\\u003C100.\n5. Patient must be ≥ 18 years of age.\n6. Patient must have a life expectancy ≥ 12 months.\n7. Patient must have an ECOG performance status ≤ 2.\n8. Patient must have the ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Castration-resistant prostate cancer (CRPC).\n2. Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy\n3. Spinal cord compression or impending spinal cord compression.\n4. Suspected pulmonary and\u002For liver metastases (greater \\>10 mm in largest axis).\n5. Patient receiving any other investigational agents.\n6. Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist .\n7. Unable to lie flat during or tolerate PET\u002FMRI, PET\u002FCT or SABR.\n8. No radiographical evidence of cranial metastasis.\n9. Refusal to sign informed consent.","MALE","18 Years",{"count":198,"type":199},122,"ESTIMATED","INTERVENTIONAL",[202],"PHASE2","This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.",[205,206],"Prostate Cancer","Oligometastatic Disease","2026-05-29",{"date":209,"type":210},"2026-06-03","ACTUAL",{"date":212,"type":210},"2022-10-18",{"date":214,"type":199},"2029-07-31",{"name":5,"class":6},10]